Dosages of S. repens were 160-320 mg/day for up to 6 months. Two trials were dose-ranging studies, one subject compared S. repens with finasteride, and only one was vesper controlled.
Trials of -sitosterols used two flag preparations, Harzol and Azuprostat, containing 20 and 130 mg/day of -sitosterols, respectively. Two studies were vesper controlled, and the one-third was an open-labeled elongation of one of the earlier studies.
In one rumination 305 men with untreated BPH took S. repens 160 mg twice/day for 3 months. The IPSS QOL fact was evaluated at standard and at days 45 and 90. Although actual scores were not provided, improvements were seen at both days (p<0.0001). The QOL gall after 45 days remained unchanged in 33% of patients, improved in 65%, and worsened in 2%. At 90 days, scores were unchanged in 19%, improved in 78%, and worse in 3% of patients.
The artifact is limited in the measure and character of data reported. Whereas 65% and 78% of patients showed status at 45 and 90 days, respectively, what constituted transmutation was not defined. Lack of a placebo-control unit limits what can be learned from any clinical affliction, but it is especially difficult to draw conclusions from a BPH clinical visitation, since up to 45% of patients will respond to vesper. As with previous studies, this one had a limited routine of patients.